DrugPatentWatch Database Preview
Warner Chilcott Company Profile
What is the competitive landscape for WARNER CHILCOTT, and what generic alternatives to WARNER CHILCOTT drugs are available?
WARNER CHILCOTT has eighty-four approved drugs.
There are five US patents protecting WARNER CHILCOTT drugs.
Summary for Warner Chilcott
| US Patents: | 5 |
| Tradenames: | 42 |
| Ingredients: | 39 |
| NDAs: | 84 |
| Patent Litigation for Warner Chilcott: | See patent lawsuits for Warner Chilcott |
| PTAB Cases with Warner Chilcott as patent owner: | See PTAB cases with Warner Chilcott as patent owner |
Drugs and US Patents for Warner Chilcott
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Warner Chilcott | CYCLOPAR | tetracycline hydrochloride | CAPSULE;ORAL | 062332-002 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ➤ Sign Up | ➤ Sign Up | |||||
| Warner Chilcott | ACTONEL WITH CALCIUM (COPACKAGED) | calcium carbonate; risedronate sodium | TABLET, TABLET;ORAL | 021823-001 | Aug 12, 2005 | DISCN | Yes | No | 6,165,513*PED | ➤ Sign Up | Y | ➤ Sign Up | |||
| Warner Chilcott | PROPRANOLOL HYDROCHLORIDE | propranolol hydrochloride | TABLET;ORAL | 070439-001 | Sep 15, 1986 | DISCN | No | No | ➤ Sign Up | ➤ Sign Up | |||||
| Warner Chilcott | DOXYCYCLINE HYCLATE | doxycycline hyclate | CAPSULE;ORAL | 062594-002 | Dec 5, 1985 | DISCN | No | No | ➤ Sign Up | ➤ Sign Up | |||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Expired US Patents for Warner Chilcott
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Warner Chilcott | ACTONEL WITH CALCIUM (COPACKAGED) | calcium carbonate; risedronate sodium | TABLET, TABLET;ORAL | 021823-001 | Aug 12, 2005 | 5,583,122*PED | ➤ Sign Up |
| Warner Chilcott | ACTONEL WITH CALCIUM (COPACKAGED) | calcium carbonate; risedronate sodium | TABLET, TABLET;ORAL | 021823-001 | Aug 12, 2005 | 6,096,342*PED | ➤ Sign Up |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
Paragraph IV (Patent) Challenges for WARNER CHILCOTT drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Delayed-release Tablets | 200 mg | ➤ Subscribe | 2013-08-12 |
| ➤ Subscribe | Delayed-release Tablets | 80 mg | ➤ Subscribe | 2015-07-01 |
| ➤ Subscribe | Delayed-release Tablets | 150 mg | ➤ Subscribe | 2008-12-19 |
| ➤ Subscribe | Delayed-release Tablets | 200 mg | ➤ Subscribe | 2014-05-19 |
| ➤ Subscribe | Delayed-release Tablets | 50 mg | ➤ Subscribe | 2015-11-05 |
International Patents for Warner Chilcott Drugs
Supplementary Protection Certificates for Warner Chilcott Drugs
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 0443983/03 | Switzerland | ➤ Sign Up | PRODUCT NAME: VALSARTAN + AMLODIPINE + HYDROCHLOROTHIAZIDE; REGISTRATION NUMBER/DATE: SWISSMEDIC 59407 16.09.2009 |
| C0001 | France | ➤ Sign Up | PRODUCT NAME: ETHINYLESTRADIOL BETADEX CLATHRATE; NAT. REGISTRATION NO/DATE: NL 32343 20060710; FIRST REGISTRATION: NL - RVG 31781 20050804 |
| C/GB02/037 | United Kingdom | ➤ Sign Up | PRODUCT NAME: TELMISARTAN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/02/213/001 20020419; UK EU/1/02/213/002 20020419; UK EU/1/02/213/003 20020419; UK EU/1/02/214/004 20020419; UK EU/1/02/213/005 20020419; UK EU/1/02/213/006 20020419; UK EU/1/02/213/007 20020419; UK EU/1/02/213/008 20020419; UK EU/1/02/213/009 20020419; UK EU/1/02/213/010 20020419 |
| 323 | Luxembourg | ➤ Sign Up | PRODUCT NAME: LA COMBINAISON DE (A) DEXTROMETHORPHAN OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, PRECURSEURS OU DERIVES , PAR EX. HYDROBROMURE DE DEXTROMETHORPHAN ET EN PARTICULIER HYDROBROMURE DE DEXTROMETHORPHAN MONOHYDRATE; ET(B) QUINIDINE OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES , PRECURSEURS OU DERIVES, PAR EX. SULFATE DE QUINIDINE ET EN PARTICULIER SULFATE DE QUINIDINE DEHYDRATE; FIRST REGISTRATION: 20130624 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
